- Home
- AVIR vs QTRX Comparison
AVIR vs QTRX Comparison
Compare AVIR & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- QTRX
- Stock Information
- Founded
- AVIR 2012
- QTRX 2007
- Country
- AVIR United States
- QTRX United States
- Employees
- AVIR N/A
- QTRX N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- AVIR Health Care
- QTRX Industrials
- Exchange
- AVIR Nasdaq
- QTRX Nasdaq
- Market Cap
- AVIR 273.7M
- QTRX 233.5M
- IPO Year
- AVIR 2020
- QTRX 2017
- Fundamental
- Price
- AVIR $2.55
- QTRX $4.28
- Analyst Decision
- AVIR Hold
- QTRX Buy
- Analyst Count
- AVIR 1
- QTRX 5
- Target Price
- AVIR $6.00
- QTRX $15.60
- AVG Volume (30 Days)
- AVIR 532.5K
- QTRX 730.1K
- Earning Date
- AVIR 05-12-2025
- QTRX 05-12-2025
- Dividend Yield
- AVIR N/A
- QTRX N/A
- EPS Growth
- AVIR N/A
- QTRX N/A
- EPS
- AVIR N/A
- QTRX N/A
- Revenue
- AVIR N/A
- QTRX $135,688,000.00
- Revenue This Year
- AVIR N/A
- QTRX $4.45
- Revenue Next Year
- AVIR N/A
- QTRX $15.48
- P/E Ratio
- AVIR N/A
- QTRX N/A
- Revenue Growth
- AVIR N/A
- QTRX 7.71
- 52 Week Low
- AVIR $2.60
- QTRX $4.67
- 52 Week High
- AVIR $4.15
- QTRX $19.18
- Technical
- Relative Strength Index (RSI)
- AVIR 37.12
- QTRX 33.96
- Support Level
- AVIR $2.66
- QTRX $5.26
- Resistance Level
- AVIR $3.01
- QTRX $5.83
- Average True Range (ATR)
- AVIR 0.15
- QTRX 0.53
- MACD
- AVIR -0.03
- QTRX -0.07
- Stochastic Oscillator
- AVIR 7.02
- QTRX 6.90
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.